Fact CheckerSign in

NCT07163936Not yet recruiting

Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Source: ClinicalTrials.gov · Last updated 16 Sept 2026

Brief summary (registry, in English)

The goal of this clinical trial is to find out if using a citrate-based dialysate with added magnesium during hemodialysis can help slow down or prevent the hardening of blood vessels (vascular calcification) in adults on long-term dialysis. The main questions the study will try to answer are: Does citrate-based dialysate with magnesium improve the blood's ability to prevent calcium buildup (measured by a test called T50) compared to acetate-based dialysate? Does it modify magnesium, calcium and parathyroid hormone (PTH) levels in the blood? Does it lower the chances of heart problems or death? Researchers will compare two groups: one will receive acetate-based dialysate, and the other will receive citrate-based dialysate with magnesium. Participants will: Receive one of the two types of dialysate during their regular hemodialysis sessions for 12 months Have regular blood tests Be monitored for any heart problems and for overall health during the study

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
80 (estimated)
First submitted
1 Sept 2025
Start date
2 Jan 2027
Primary completion date
2 Jan 2028
Lead sponsor
Hospital Clinic of Barcelona
NCT number
NCT07163936

What you commit to

  • Study type: Interventional
  • Planned participants: 80
  • From 2 Jan 2027 to the primary completion date, 2 Jan 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Planned living donor kidney transplant before study completion
  • Current treatment with vitamin K antagonists (coumarins)

Other illness

  • Known allergy or intolerance to any component of the dialysates
  • Active malignancy or infectious/inflammatory disease
  • Any condition that, in the investigator's judgment, contraindicates participation or affects study compliance

Other

  • Severe hypocalcemia or poorly controlled secondary hyperparathyroidism

Who the study is looking for

  • Adults (≥18 years old) on maintenance hemodialysis for more than 3 months
  • Clinically stable patients with a well-functioning vascular access
  • Residual urine output ≤ 250 mL/day
  • Able and willing to provide written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.